Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Center Trial to Assess the Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines (SAKURA OPEN-LABEL SAFETY)

NCT03004248 is registered in ClinicalTrials.gov with Revance Therapeutics, Inc. as lead sponsor.

NCT NCT03004248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03004248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Center Trial to Assess the Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines (SAKURA OPEN-LABEL SAFETY)
Lead sponsor
Revance Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 9, 2016
Completion date
October 17, 2018
Enrollment
2,691 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar frown lines